Marinus Pharmaceuticals Inc’s recent filing unveils that its CFO AND COO Pfanstiel Steven unloaded Company’s shares for reported $5262.0 on Aug 05 ’24. In the deal valued at $1.13 per share,4,657 shares were sold. As a result of this transaction, Pfanstiel Steven now holds 79,773 shares worth roughly $24729.63.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Shafer Christina sold 3,820 shares, generating $4,355 in total proceeds. Upon selling the shares at $1.14, the CHIEF COMMERCIAL OFFICER now owns 67,406 shares.
Before that, MANNING MARTHA E sold 3,621 shares. Marinus Pharmaceuticals Inc shares valued at $4,092 were divested by the SVP, GEN. COUNSEL & CORP. SEC. at a price of $1.13 per share. As a result of the transaction, MANNING MARTHA E now holds 60,263 shares, worth roughly $18681.53.
Oppenheimer upgraded its Marinus Pharmaceuticals Inc [MRNS] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Ladenburg Thalmann’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Neutral”. Robert W. Baird also remained covering MRNS and has decreased its forecast on April 16, 2024 with a “Neutral” recommendation from previously “an Outperform” rating. RBC Capital Mkts revised its rating on April 15, 2024. It rated MRNS as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of MRNS
On Tuesday, Marinus Pharmaceuticals Inc [NASDAQ:MRNS] saw its stock fall -6.35% to $0.31. Over the last five days, the stock has lost -4.85%. Marinus Pharmaceuticals Inc shares have fallen nearly -97.17% since the year began. Nevertheless, the stocks have fallen -95.79% over the past one year. While a 52-week high of $11.26 was reached on 01/08/24, a 52-week low of $0.26 was recorded on 10/25/24. SMA at 50 days reached $0.9567, while 200 days put it at $2.7274.
Levels Of Support And Resistance For MRNS Stock
The 24-hour chart illustrates a support level at 0.2938, which if violated will result in even more drops to 0.2796. On the upside, there is a resistance level at 0.3216. A further resistance level may holdings at 0.3352. The Relative Strength Index (RSI) on the 14-day chart is 27.09, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0051, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 63.80%. Stochastics %K at 44.29% indicates the stock is a holding.
How much short interest is there in Marinus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Marinus Pharmaceuticals Inc stocks on 2024-10-31, growing by 2.44 million shares to a total of 5.66 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.22 million shares. There was a rise of 43.12%, which implies that there is a positive sentiment for the stock.
